05.02.2010 • News

Change in Management at Inprocess Instruments

Dr. Andreas Pickuth succeeds Wolfgang Hrosch in the management at Inprocess Instruments Gesellschaft für Prozessanalytik, headquartered in Bremen,Germany. Twelve years after founding the company, Wolfgang Hrosch is retiring from operative management, but will continue to be an active partner in an advisory capacity. Bernd Laser remains unaltered the managing partner responsible for the company's production department.

Dr. Andreas Pickuth, born in Hamburg in 1956, is a graduate physicist. He obtained his doctorate at the Institute for Applied Physics at the University of Hamburg. In 1989 he joined Maihak , Hamburg, a globally acting company in the field of process and environmental engineering. There he worked as head of Product Management and Application Laboratory, for the Department of International Business Development and, lastly, as head of international Sales Management. After Sick acquired Maihak in 2000, Andreas Pickuth took on additional responsibilities in international market management and was appointed to a variety of board of directors positions of internationally active associated companies and subsidiaries, particularly in the Asian region.

Company

InProcess Instruments

Otto-Lilienthal-Str. 16
28199 Bremen
Germany

Company contact







Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read